Skip to main navigation Skip to search Skip to main content

Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD)

  • M. Patricia Hidalgo
  • , Carlos A. Celis
  • , Maria Ximena Rojas-Reyes
  • , Rodolfo J. Dennis

Research output: Contribution to JournalReview articlepeer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness and safety of once-daily LABA/ICS in a combined inhaler versus once/twice-daily LABA for the treatment of COPD.

Original languageEnglish (US)
Article numberCD012100
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number2
DOIs
StatePublished - Feb 29 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD)'. Together they form a unique fingerprint.

Cite this